Hemogenyx Pharmaceuticals Plc said Robin Campbell would resign as a nonexecutive director, effective Jan. 5, 2019.
London-based Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company that focuses on the discovery, development and commercialization of novel therapies and treatments for blood diseases.